Crispr Therapeutics AG (CRSP)

77.98
-0.81(-1.03%)
After Hours
78.40
+0.42(+0.54%)
- Real-time Data
  • Volume:
    1,397,007
  • Bid/Ask:
    77.90/78.40
  • Day's Range:
    76.71 - 80.75

CRSP Overview

Prev. Close
78.79
Day's Range
76.71-80.75
Revenue
902.43M
Open
79.58
52 wk Range
76.71-220.2
EPS
4.76
Volume
1,397,007
Market Cap
5.97B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,352,331
P/E Ratio
16.55
Beta
2.07
1-Year Change
-35.85%
Shares Outstanding
76,526,964
Next Earnings Date
Mar 11, 2022
What is your sentiment on Crispr Therapeutics AG?
or
Market is currently closed. Voting is open during market hours.

Crispr Therapeutics AG Company Profile

Employees
410

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-fda-regenerative-medicine-advanced
    0
    • Amazing how fast this went from breakthrough life changing technology to garbage in about a month
      0
      • One paragraph of good news and this goes back to 160 in a day after the sheep pile in. Not just this ticker but any of them.
        0
        • Added 1100 shares
          2
          • now u must be regretting
            0
          • nope I'm long!
            0
        • keep tanking this stock what a hopeless
          5
          • Ouch
            0
            • In few weaks 120
              0
              • why are you so sure Mr. John Doe ? please ?
                0
              • Possible. 102 is more likely. If it does approach 120, breaking 124 resistance will be a signifant upside challenge.
                0
              • in 4 weeks 85
                2
            • ouch. well since we're here.. i might as well average down
              0
              • median bollinger band is broken on monthly TF... waiting the end of october...
                1
                • 97 usd  is a good entry point...
                  4
                  • a classic Cathy wood collapse
                    8
                    • how do you actually buy shares i have a buy sell window open but its an ad i wanna actually buy a stock not be sent to yet another bs broker app
                      1
                      • Check if you Bank can help you out
                        0
                      • Open and fund a brokerage account. There are many options.
                        0
                    • wow
                      0
                      • Beat on earnings!! Largly
                        0
                        • Problem with this one is you're gonna need to wait a literal decade for it to be viable, regardless of studies/tests.
                          0
                          • true
                            0
                          • I think in a normal world… Definitely. My opinion, it right around the corner.
                            0
                        • total bubble of cathie wollod pump
                          3
                          • CRSP and AIRI are Good stockAIRI will go up to X3
                            0
                            • keep on dropping...
                              0
                              • good entry point is around 80
                                2
                                • keep dropping, want to get back in
                                  0
                                  • 206 by Oct
                                    2
                                    • That would be acceptable.
                                      0
                                  • Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome editing in humans. We summarise the findings here.
                                    0
                                    • ride it to new highs
                                      1
                                      • Alert: Crispr Therapeutics will acquire AGTC before end of FY2021 as a strategy to get into the ophthalmology space. Load up now & Stay tuned
                                        0
                                        • ok, thanks
                                          0
                                        • Thank you, but may we know your source, please?
                                          0
                                        • What proof or source do you have that these facts have changed? See quote:  Gene therapy developer AGTC lost nearly half its market cap Thursday morning after Biogen exited a collaboration agreement on the heels of a big clinical failure. Interim six-month data on one of AGTC's investigational therapies showed it was generally safe but ineffective at treating a rare eye disorder known as X-linked retinoschisis (XLRS). The company plans to complete patient monitoring activities on the XLRS program but will not develop it further.
                                          0
                                      • Held the dip, looks great
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.